JPH11501804A - 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 - Google Patents
免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法Info
- Publication number
- JPH11501804A JPH11501804A JP8525496A JP52549696A JPH11501804A JP H11501804 A JPH11501804 A JP H11501804A JP 8525496 A JP8525496 A JP 8525496A JP 52549696 A JP52549696 A JP 52549696A JP H11501804 A JPH11501804 A JP H11501804A
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- protein
- papillomavirus
- hpv
- sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.溶液又は分散液の形態の場合に滅菌フィルターを通過することができる凝 集形態又はアモルファス凝集形態における、パピローマウイルス蛋白質の抗原決 定基を含むポリペプチド又はポリペプチド組成物。 2.少くとも2種類のパピローマウイルス蛋白質の抗原決定基、例えばL2と 他のもの、又はE7と他のものを含むことを特徴とする請求項1に記載のポリペ プチド又はポリペプチド組成物。 3.少くとも1種類のパピローマウイルスL2蛋白質の抗原決定基と、少くと も1種類のパピローマウイルスE1,E2,E4,E6又はE7蛋白質の抗原決 定基と、を含むことを特徴とする請求項1又は2に記載のポリペプチド又はポリ ペプチド組成物。 4.HPV のL2及びE7蛋白質の抗原決定基を含み、例えばL2蛋白質及びE 7蛋白質の各々の全配列の少くとも50%の配列フラグメントを含み、例えばL2 及びE7の実質的に全配列を含み、必要に応じて更にL1蛋白質の配列を含むこ とを特徴とする請求項1,2、又は3に記載のポリペプチド又はポリペプチド組 成物。 5.前記抗原決定基が、HPV タイプ6,11,16,18のパピローマウイルス蛋白 質のもの又は非ヒト動物パピローマウイルスのものであることを特徴とする先の 請求項のいずれかに記載のポリペプチド又はポリペプチド組成物。 6.変性され、還元され、そして再凝集された調製物の形態における先の請求 項のいずれかに記載のポリペプチド又はポリペプチド組成物。 7.変性、又は還元での変性、及び次の組換え宿主細胞内の封入体の形態で発 現されたポリペプチドの再凝集により得られうる先の 請求項のいずれかに記載のポリペプチド又はポリペプチド組成物。 8.約 100,000〜約10,000,000ダルトンの範囲の凝集物当りの分子量を有する ことを特徴とする請求項7に記載のポリペプチド又はポリペプチド組成物。 9.約4〜50mm、例えば約10〜15mmの範囲の電子顕微鏡での直径を有する凝集 粒子を含むことを特徴とする請求項7に記載のポリペプチド又はポリペプチド組 成物。 10.凝集物当り2〜200 、例えば5〜50ポリペプチド鎖を有する凝集粒子を含 むことを特徴とする請求項7に記載のポリペプチド又はポリペプチド組成物。 11.(a)少くともパピローマウイルスL2蛋白質の抗原決定基と、(b)少 くともE1,E2,E4,E5,E6及びE7パピローマウイルス蛋白質並びに (a)と異なるパピローマウイルスタイプのL2パピローマウイルス蛋白質から 選択される抗原決定基と、を含むか;又はE1,E2,E4,E5,E6及びE 7パピローマウイルス蛋白質から選択される少くとも2種類のパピローマウイル ス蛋白質からの抗原決定基を含み、ここで例えば前記蛋白質が異なるパピローマ ウイルスタイプからのものであることを特徴とするポリペプチド又はポリペプチ ド組成物。 12.L2蛋白質の抗原決定基と、E1,E2,E4,E6及びE7蛋白質の少 くとも1種類からの抗原決定基と、を含む融合ポリペプチドを含むことを特徴と する請求項11に記載のポリペプチド又はポリペプチド組成物。 13.免疫学的アジュバントと一緒に先の請求項のいずれかに記載のポリペプチ ドを含むことを特徴とする注入による投与に適した免疫原性組成物。 14.前記アジュバントが、水酸化アルミニウム及び/又はモノホ スホリル脂質Aを含むことを特徴とする請求項13に記載の免疫原性組成物。 15.免疫原として、例えばパピローマウイルス関連状態の予防又は治療のため のワクチンとしての先の請求項のいずれかに記載のポリペプチド又は免疫原性組 成物の使用。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9503786.7A GB9503786D0 (en) | 1995-02-24 | 1995-02-24 | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
US3495P | 1995-06-08 | 1995-06-08 | |
GB9503786.7 | 1995-07-28 | ||
GB9515478.7 | 1995-07-28 | ||
GB60/000,034 | 1995-07-28 | ||
GBGB9515478.7A GB9515478D0 (en) | 1995-07-28 | 1995-07-28 | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
PCT/GB1996/000397 WO1996026277A1 (en) | 1995-02-24 | 1996-02-23 | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH11501804A true JPH11501804A (ja) | 1999-02-16 |
JP3958360B2 JP3958360B2 (ja) | 2007-08-15 |
Family
ID=27267602
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP52549696A Expired - Fee Related JP3958360B2 (ja) | 1995-02-24 | 1996-02-23 | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 |
Country Status (6)
Country | Link |
---|---|
US (2) | US5955087A (ja) |
EP (1) | EP0812358A1 (ja) |
JP (1) | JP3958360B2 (ja) |
AU (1) | AU4727296A (ja) |
CA (1) | CA2211995A1 (ja) |
WO (1) | WO1996026277A1 (ja) |
Families Citing this family (72)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2202090C (en) * | 1994-10-07 | 2012-04-17 | Lutz Gissmann | Papilloma virus-like particles, fusion proteins as well as processes for their production |
AUPN443995A0 (en) * | 1995-07-27 | 1995-08-17 | Csl Limited | Papillomavirus polyprotein |
WO1998004706A1 (en) * | 1996-07-29 | 1998-02-05 | Cantab Pharmaceuticals Research Limited | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation |
DE19631357A1 (de) * | 1996-08-02 | 1998-02-05 | Deutsches Krebsforsch | Vektor zur Aktivierung des Immunsystems gegen mit Papillomviren bzw. Sequenzen davon assoziierten Zellen |
AU4258297A (en) * | 1996-09-11 | 1998-04-02 | Merck & Co., Inc. | Papillomavirus vaccine formulation |
GB9621091D0 (en) | 1996-10-09 | 1996-11-27 | Fondation Pour Le Perfectionem | Attenuated microorganisms strains and their uses |
US7157089B1 (en) | 1996-11-26 | 2007-01-02 | Stressgen Biotechnologies Corporation | Immune responses using compositions containing stress proteins |
DE19649604C1 (de) * | 1996-11-29 | 1997-09-25 | Deutsches Krebsforsch | Verfahren zur Reinigung und Rückfaltung von HPV-Proteinen |
EP0957936B1 (en) * | 1996-12-20 | 2006-10-04 | MERCK & CO., INC. | Formulations of recombinant papillomavirus vaccines |
ATE235890T1 (de) * | 1997-01-30 | 2003-04-15 | Chiron Corp | Verwendung von mikropartikeln mit adsorbiertem antigen zur stimulierung der immunabwehr |
ATE327259T1 (de) | 1997-08-05 | 2006-06-15 | Stressgen Biotechnologies Corp | Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine |
GB9717953D0 (en) * | 1997-08-22 | 1997-10-29 | Smithkline Beecham Biolog | Vaccine |
IL135989A0 (en) * | 1997-11-14 | 2001-05-20 | Skyepharma Inc | Processes for the production of multivesicular liposomes |
CA2339324C (en) * | 1998-08-14 | 2011-05-31 | Robert S. Lowe | Protein delivery system using human papillomavirus virus-like particles |
TR200101055T2 (tr) * | 1998-10-16 | 2001-09-21 | Smithkline Beecham Biologicals S.A. | Adjuvan sistemler ve aşılar |
DE19905883C2 (de) * | 1999-02-11 | 2001-05-23 | Deutsches Krebsforsch | Chimäre Virus-ähnliche Partikel bzw. chimäre Capsomere von BPV |
NZ515322A (en) * | 1999-05-13 | 2004-03-26 | Wyeth Corp | Adjuvant combination formulations |
US20050175634A1 (en) * | 1999-06-25 | 2005-08-11 | The Board Of Trustees Of The University Of Arkansas | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
US6350451B1 (en) * | 1999-06-25 | 2002-02-26 | The Board Of Trustees Of The University Of Arkansas | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
CA2276219A1 (en) * | 1999-06-25 | 2000-12-25 | Board Of Trustees Of The University Of Arkansas | Immunotherapy of epithelial tumors using intralesional injection of antigens that induce a delayed type hypersensitivity reaction |
US6495347B1 (en) | 1999-07-08 | 2002-12-17 | Stressgen Biotechnologies Corporation | Induction of a Th1-like response in vitro |
US7001995B1 (en) * | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
GB9921146D0 (en) * | 1999-09-07 | 1999-11-10 | Smithkline Beecham Biolog | Novel composition |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
PT1296711E (pt) | 2000-06-26 | 2006-08-31 | Stressgen Biotechnologies Corp | E7 de vph para o tratamento do virus do papiloma humano |
ES2275699T3 (es) * | 2000-07-07 | 2007-06-16 | MERCK & CO., INC. | Produccion de un papilomavirus humano(hpv) quimerico. |
CZ20031225A3 (cs) * | 2000-11-10 | 2003-10-15 | Wyeth Holdings Corporation | Adjuvantní kombinované prostředky |
GB0105606D0 (en) * | 2001-03-07 | 2001-04-25 | Cantab Pharmaceuticals Res Ltd | Immunogens and vaccines and their preparation and use |
GB0109297D0 (en) | 2001-04-12 | 2001-05-30 | Glaxosmithkline Biolog Sa | Vaccine |
FR2828404B1 (fr) * | 2001-08-10 | 2005-07-15 | Neovacs | Superimmunogene composite a usage vaccinal bifonctionnel pour le traitement des maladies associees a un desordre tissulaire stromal |
US20050075298A1 (en) * | 2002-01-31 | 2005-04-07 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the intestinal mucosa |
US20040009937A1 (en) * | 2002-01-31 | 2004-01-15 | Wei Chen | Methods and composition for delivering nucleic acids and/or proteins to the respiratory system |
US20040043003A1 (en) * | 2002-01-31 | 2004-03-04 | Wei Chen | Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions |
GB0206359D0 (en) * | 2002-03-18 | 2002-05-01 | Glaxosmithkline Biolog Sa | Viral antigens |
US7476222B2 (en) * | 2003-06-30 | 2009-01-13 | Johnson & Johnson Consumer Companies, Inc. | Methods of reducing the appearance of pigmentation with galvanic generated electricity |
AU2006338570B2 (en) * | 2005-11-18 | 2013-07-11 | The Ohio State University Research Foundation | Viral gene products and methods for vaccination to prevent viral associated diseases |
TWI457133B (zh) | 2005-12-13 | 2014-10-21 | Glaxosmithkline Biolog Sa | 新穎組合物 |
US8101342B2 (en) * | 2006-08-28 | 2012-01-24 | Sungkyunkwan University Foundation For Corporate Collaboration | DNA vaccine for treating or preventing cervical cancer comprising a gene encoding HPV protein |
US20090181078A1 (en) | 2006-09-26 | 2009-07-16 | Infectious Disease Research Institute | Vaccine composition containing synthetic adjuvant |
DK2068918T3 (da) | 2006-09-26 | 2012-07-30 | Infectious Disease Res Inst | Vaccinesammensætning omfattende syntetisk adjuvant |
WO2008043774A1 (en) | 2006-10-12 | 2008-04-17 | Glaxosmithkline Biologicals S.A. | Vaccine comprising an oil in water emulsion adjuvant |
PL2086582T3 (pl) | 2006-10-12 | 2013-04-30 | Glaxosmithkline Biologicals Sa | Kompozycja zawierająca adiuwant w postaci emulsji typu olej w wodzie |
PL2137210T3 (pl) | 2007-03-02 | 2017-06-30 | Glaxosmithkline Biologicals Sa | Nowy sposób i kompozycje |
US9717788B2 (en) | 2007-03-02 | 2017-08-01 | Glaxosmithkline Biologicals Sa | Method of inducing an immune response against HIV employing HIV immunogens, adenoviral vectors encoding said immunogens, and adjuvant |
US9452209B2 (en) | 2007-04-20 | 2016-09-27 | Glaxosmithkline Biologicals Sa | Influenza vaccine |
GB0815872D0 (en) | 2008-09-01 | 2008-10-08 | Pasteur Institut | Novel method and compositions |
RU2560182C2 (ru) | 2009-06-05 | 2015-08-20 | Инфекшес Дизиз Рисерч Инститьют | Синтетические глюкопиранозиллипидные адъюванты |
SG184310A1 (en) | 2010-04-13 | 2012-10-30 | Celldex Therapeutics Inc | Antibodies that bind human cd27 and uses thereof |
MX350795B (es) | 2011-04-08 | 2017-09-19 | Inmune Design Corp | Composiciones inmunogenicas y metodos para utilizar las composiciones para inducir respuestas inmunes humorales y celulares. |
TR201908003T4 (tr) | 2012-02-07 | 2019-06-21 | Infectious Disease Res Inst | TLR4 agonistleri içeren gelişmiş adjuvan formülasyonları ve bunların kullanım metotları. |
NZ701881A (en) | 2012-05-16 | 2016-10-28 | Immune Design Corp | Vaccines for hsv-2 |
SG11201508092YA (en) | 2013-04-18 | 2015-10-29 | Immune Design Corp | Gla monotherapy for use in cancer treatment |
US9463198B2 (en) | 2013-06-04 | 2016-10-11 | Infectious Disease Research Institute | Compositions and methods for reducing or preventing metastasis |
JP6741580B2 (ja) | 2013-12-31 | 2020-08-19 | インフェクシャス ディズィーズ リサーチ インスティチュート | 単一バイアルのワクチン製剤 |
EP3268037B1 (en) | 2015-03-09 | 2022-08-31 | Celldex Therapeutics, Inc. | Cd27 agonists |
SG11201808821WA (en) | 2016-04-18 | 2018-11-29 | Celldex Therapeutics Inc | Agonistic antibodies that bind human cd40 and uses thereof |
JP7195148B2 (ja) | 2016-05-16 | 2022-12-23 | アクセス ツー アドバンスト ヘルス インスティチュート | Tlrアゴニストを含有する製剤及び使用方法 |
CA3023672A1 (en) | 2016-05-16 | 2017-11-23 | Infectious Disease Research Institute | Pegylated liposomes and methods of use |
IL298227B1 (en) | 2016-06-01 | 2024-05-01 | Access To Advanced Health Inst | Nanoalum particles containing a fixing factor |
CN111315362A (zh) | 2017-06-15 | 2020-06-19 | 传染病研究所 | 纳米结构脂质载剂和稳定乳剂以及其用途 |
KR20200066309A (ko) | 2017-09-08 | 2020-06-09 | 인펙셔스 디지즈 리서치 인스티튜트 (아이디알아이) | 사포닌을 포함하는 리포솜 제형 및 사용 방법 |
CN112292185A (zh) | 2018-04-17 | 2021-01-29 | 塞德斯医疗公司 | 抗cd27和抗pd-l1抗体及双特异性构建体 |
US20220016168A1 (en) | 2018-12-11 | 2022-01-20 | Celldex Therapeutics, Inc. | Methods of using cd27 antibodies as conditioning treatment for adoptive cell therapy |
AU2020283768A1 (en) | 2019-05-25 | 2021-12-23 | Access To Advanced Health Institute | Composition and method for spray drying an adjuvant vaccine emulsion |
CA3174411A1 (en) | 2020-09-04 | 2022-03-10 | Ryan M. Kramer | Co-lyophilized rna and nanostructured lipid carrier |
US11033495B1 (en) | 2021-01-22 | 2021-06-15 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11357727B1 (en) | 2021-01-22 | 2022-06-14 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
US11278494B1 (en) | 2021-01-22 | 2022-03-22 | Pacira Pharmaceuticals, Inc. | Manufacturing of bupivacaine multivesicular liposomes |
KR20240006541A (ko) | 2021-04-09 | 2024-01-15 | 셀덱스 쎄라퓨틱스, 인크. | Ilt4에 대한 항체, 이중특이적 항-ilt4/pd-l1 항체 및 이의 용도 |
WO2023077521A1 (en) | 2021-11-08 | 2023-05-11 | Celldex Therapeutics, Inc | Anti-ilt4 and anti-pd-1 bispecific constructs |
CN114134165B (zh) * | 2022-01-27 | 2022-04-29 | 北京循生生物医学研究有限公司 | 一种新型hpv治疗性核酸疫苗 |
WO2024052882A1 (en) | 2022-09-09 | 2024-03-14 | Access To Advanced Health Institute | Immunogenic vaccine composition incorporating a saponin |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1992005248A1 (en) * | 1990-09-26 | 1992-04-02 | Bristol-Myers Squibb Company | Human papilloma viral protein expression for use in vaccine compositions |
JPH04217998A (ja) * | 1990-03-20 | 1992-08-07 | Behringwerke Ag | ヒトパピローマウイルス16タン白質の血清反応性エピトープ |
JPH04227000A (ja) * | 1990-05-10 | 1992-08-17 | Behringwerke Ag | ヒトパピローマウイルス18のタンパク質における血清反応性エピトープ |
JPH04505452A (ja) * | 1989-05-30 | 1992-09-24 | コモンウェルス サイエンティフィク アンド インダストリアル リサーチ オーガナイゼイション | 高免疫原性形態のibdv vp2の生産 |
WO1993002184A1 (en) * | 1991-07-19 | 1993-02-04 | The University Of Queensland | Papilloma virus vaccine |
JPH05506145A (ja) * | 1990-04-06 | 1993-09-16 | コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション | 修飾ポチウイルス外被タンパク質に基づく自己ポリマー化発現系 |
WO1993020844A1 (en) * | 1992-04-08 | 1993-10-28 | Cancer Research Campaign Technology Ltd. | Papillomavirus e7 protein |
JPH06505626A (ja) * | 1991-03-14 | 1994-06-30 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 組換えウイルスベクター |
WO1994020137A1 (en) * | 1993-03-09 | 1994-09-15 | University Of Rochester | Production of human papillomavirus capsid protein and virus-like particles |
JPH06508988A (ja) * | 1991-06-26 | 1994-10-13 | キャンサー リサーチ キャンペーン テクノロジー リミティド | 乳頭腫ウイルスl2蛋白 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4766224A (en) * | 1985-08-19 | 1988-08-23 | International Minerals & Chemical Corp. | Purification and activation of proteins from insoluble inclusion bodies |
US5618536A (en) * | 1992-09-03 | 1997-04-08 | The United States Of America As Represented By The Department Of Health And Human Services | Chimeric papillomavirus-like particles |
-
1996
- 1996-02-23 CA CA002211995A patent/CA2211995A1/en not_active Abandoned
- 1996-02-23 EP EP96903127A patent/EP0812358A1/en not_active Withdrawn
- 1996-02-23 JP JP52549696A patent/JP3958360B2/ja not_active Expired - Fee Related
- 1996-02-23 US US08/606,288 patent/US5955087A/en not_active Expired - Lifetime
- 1996-02-23 WO PCT/GB1996/000397 patent/WO1996026277A1/en active Application Filing
- 1996-02-23 AU AU47272/96A patent/AU4727296A/en not_active Abandoned
-
1999
- 1999-07-02 US US09/347,483 patent/US6123948A/en not_active Expired - Fee Related
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04505452A (ja) * | 1989-05-30 | 1992-09-24 | コモンウェルス サイエンティフィク アンド インダストリアル リサーチ オーガナイゼイション | 高免疫原性形態のibdv vp2の生産 |
JPH04217998A (ja) * | 1990-03-20 | 1992-08-07 | Behringwerke Ag | ヒトパピローマウイルス16タン白質の血清反応性エピトープ |
JPH05506145A (ja) * | 1990-04-06 | 1993-09-16 | コモンウエルス・サイエンティフィック・アンド・インダストリアル・リサーチ・オーガニゼイション | 修飾ポチウイルス外被タンパク質に基づく自己ポリマー化発現系 |
JPH04227000A (ja) * | 1990-05-10 | 1992-08-17 | Behringwerke Ag | ヒトパピローマウイルス18のタンパク質における血清反応性エピトープ |
WO1992005248A1 (en) * | 1990-09-26 | 1992-04-02 | Bristol-Myers Squibb Company | Human papilloma viral protein expression for use in vaccine compositions |
JPH06505626A (ja) * | 1991-03-14 | 1994-06-30 | キャンタブ ファーマシューティカルズ リサーチ リミティド | 組換えウイルスベクター |
JPH06508988A (ja) * | 1991-06-26 | 1994-10-13 | キャンサー リサーチ キャンペーン テクノロジー リミティド | 乳頭腫ウイルスl2蛋白 |
WO1993002184A1 (en) * | 1991-07-19 | 1993-02-04 | The University Of Queensland | Papilloma virus vaccine |
WO1993020844A1 (en) * | 1992-04-08 | 1993-10-28 | Cancer Research Campaign Technology Ltd. | Papillomavirus e7 protein |
WO1994020137A1 (en) * | 1993-03-09 | 1994-09-15 | University Of Rochester | Production of human papillomavirus capsid protein and virus-like particles |
Also Published As
Publication number | Publication date |
---|---|
US6123948A (en) | 2000-09-26 |
CA2211995A1 (en) | 1996-08-29 |
AU4727296A (en) | 1996-09-11 |
US5955087A (en) | 1999-09-21 |
WO1996026277A1 (en) | 1996-08-29 |
EP0812358A1 (en) | 1997-12-17 |
JP3958360B2 (ja) | 2007-08-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3958360B2 (ja) | 免疫治療剤として役立つポリペプチド及びポリペプチド調製の方法 | |
US5618536A (en) | Chimeric papillomavirus-like particles | |
JP5386392B2 (ja) | ひとパピローマウイルス・カプシド蛋白およびウイルス様粒子の製造 | |
JPH08504087A (ja) | 自己組立て組換えパピローマウィルスキャプシッド蛋白質 | |
MX2011013744A (es) | Construcciones novedosas de proteinas del virus de papiloma humano (hpv) y su uso en la prevencion de la enfermedad por el hpv. | |
EP1305039B1 (en) | Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof | |
US6485728B2 (en) | Formalin-Inactivated human papillomavirus L1 protein vaccine | |
US7691386B2 (en) | Chimeric papillomavirus-like particles | |
WO1998004706A1 (en) | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation | |
MXPA99000963A (en) | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation | |
KR20000029687A (ko) | 면역치료제로서유용한폴리펩티드및폴리펩티드의제조방법 | |
AU4454499A (en) | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation | |
AU717932B2 (en) | Chimeric papillomavirus-like particles | |
AU717647B2 (en) | Chimeric papillomavirus-like particles | |
AU3560202A (en) | Polypeptides useful as immunotherapeutic agents and methods of polypeptide preparation | |
AU5013099A (en) | Papillomavirus vaccine | |
AU4889102A (en) | Papillomavirus vaccine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060124 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060420 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060605 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060724 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20060905 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20061204 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20070130 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070320 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20070410 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20070510 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100518 Year of fee payment: 3 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110518 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120518 Year of fee payment: 5 |
|
LAPS | Cancellation because of no payment of annual fees |